A Perfect Match: Choosing the Right CRO Partner in Europe
Posted: February 1, 2013
By: Clinipace Worldwide
Approximately 20% of the world's clinical trials are conducted in Europe, which is defined in this context as the 30 countries that contribute to the European Medicines Agency (EMA). Compared with single countries, such as the US or Japan, the confederation of separate nations that comprise Europe can present both challenges and opportunities for clinical trials at any stage of drug development.
This paper reviews 3 key areas to consider when choosing a CRO partner:
Share this content with your network.
By clicking this 'Download Now' box, you consent to BioCentury forwarding your information
to the company that wrote this White Paper and you agree that said company can use